A meta-analysis was performed to assess randomized controlled trials comparing local endovascular therapy (with and without intravenous thrombolysis) versus standard care (intravenous thrombolysis alone when appropriate) for acute ischemic stroke. Local endovascular therapy showed a significant improvement in functional independence versus standard care (odds ratio, 1.779; 95% confidence interval, 1.262-2.507; P o .001). This benefit strengthened further on subgroup analyses of trials in which a majority of cases used stent retrievers, trials with intravenous thrombolysis use in both arms when appropriate, and trials that required preprocedural imaging of all patients. There were no significant differences between arms in terms of mortality, hemicraniectomy, intracranial hemorrhage, and cerebral edema rates (P 4 .05). In conclusion, in the treatment of acute ischemic stroke, local endovascular therapy leads to improved functional independence compared with standard care. Local mechanical and pharmacologic endovascular therapies have been extensively investigated for the treatment of acute ischemic stroke (1-7). Such therapies have been investigated as targeted, effective, and safe means of achieving arterial recanalization with the goal of improving clinical outcomes.
Local mechanical and pharmacologic endovascular therapies have been extensively investigated for the treatment of acute ischemic stroke (1) (2) (3) (4) (5) (6) (7) . Such therapies have been investigated as targeted, effective, and safe means of achieving arterial recanalization with the goal of improving clinical outcomes.
After initial observational trials demonstrated benefit for endovascular approaches, randomized controlled trials (RCTs) were performed to assess these outcomes (1) . The first RCT, Prolyse in Acute Cerebral Thromboembolism II (2) , found a statistically significant benefit from endovascular treatment of middle cerebral artery occlusion with the use of prourokinase, but the new drug required a second trial for approval by the US Food and Drug Administration. A second RCT, the Middle cerebral artery Embolism Local fibrinolytic intervention Trial (3) , again demonstrated benefit from thrombolytic therapy with urokinase, but the trial was stopped prematurely in Japan when intravenous (IV) tissue plasminogen activator (TPA) was approved and statistical significance was not yet achieved. A series of RCTs published in 2013 (4) (5) (6) demonstrated no benefit to endovascular therapy. These trials were criticized for heterogeneous patient populations, poor patient selection, inconsistent times to intervention, and low rates of stent-retriever use (7, 8) . In the past year, several large RCTs have been released that included carefully selected patient populations (9) (10) (11) (12) (13) . These trials have demonstrated positive findings in terms of benefit for functional independence for patients.
Given the discordance of results among trials, a metaanalysis was performed of all RCTs of local endovascular therapy (mechanical and/or pharmacologic) with and without IV thrombolysis compared with a standard-care control that included IV thrombolysis when appropriate.
MATERIALS AND METHODS

Systematic Search and Data Abstraction
Systematic searches for RCTs of local endovascular therapy for acute ischemic stroke in humans were performed of the MEDLINE database (1946 Secondary searches were conducted by three reviewers by reviewing citations from primary studies and review papers including previously published meta-analyses and systematic reviews.
Abstracts found in the primary and secondary literature searches were independently screened for potential studies of interest by two reviewers. Studies were limited to RCTs performed on humans of any age group and published in the English language. Inclusion criteria were decided a priori to include only RCTs that compared local endovascular therapy (mechanical and/or pharmacologic) with or without IV thrombolysis versus a standard-care control that included IV thrombolysis when appropriate. Appropriate IV thrombolysis in the standard-care arm was defined as patients being permitted to receive IV thrombolysis, if no contraindications were present, within 4.5 hours of stroke symptom onset. Trials comparing local endovascular therapy versus a placebo/ sham control arm were excluded, as IV thrombolysis was considered to be the current standard of care (14) .
Following the initial abstract screen, the full texts of the remaining trials were independently reviewed. Interreviewer disagreement regarding study inclusion was resolved by discussion with the remaining study authors to reach consensus. Data were extracted into a standardized spreadsheet in duplicate independently by two reviewers.
Quality and Strength of Recommendation Assessment
Individual study bias was assessed by using the Cochrane risk of bias tool (15) . This assessed the appropriate use of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete reporting of outcome data, selective reporting, and "other" (eg, industry funding). The Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology was used to rate the confidence in each reported outcome as high, moderate, low, or very low on the basis of five domains: overall risk of bias, imprecision, inconsistency, indirectness, and publication bias (16) . These were independently assessed by two reviewers. Disagreement was again resolved by the remaining study authors.
Statistical Analyses
Outcomes of interest were established a priori and included the percentage of patients with a modified Rankin scale (mRS) score at 90 days of 0-2, 90-day mortality rate, hemicraniectomy rate, symptomatic and fatal intracranial hemorrhage rates, and symptomatic or fatal cerebral edema rates. A 90-day mRS score of 0-2 was selected because this outcome represents functional independence for patients and has been the standard in all trials (2-6,9-13). Meta-analysis was performed when at least two RCTs existed that compared a similar treatment and control group and measured one of these prespecified outcomes. Several subgroup analyses were performed in addition to the primary meta-analysis for each outcome. The primary meta-analysis assessed all RCTs that met the aforementioned inclusion criteria. The following subgroup analyses were then performed: (i) meta-analysis of only RCTs that stated they had used preprocedural imaging selection (computed tomography [CT], magnetic resonance [MR] imaging, or catheter angiography) in both arms to identify target vessel occlusion before intervention, (ii) meta-analysis of only RCTs that reported a greater than 50% stent-retriever use rate in the endovascular arm, (iii) meta-analysis of only RCTs with isolated intraarterial TPA and/or mechanical thrombectomy without IV TPA in the endovascular arm, and (iv) meta-analysis of only RCTs that had IV TPA administered when appropriate in addition to endovascular intervention.
Meta-analyses were performed by using Comprehensive Meta Analysis software, version 2.0 (www.metaanalysis.com). Results were expressed as odds ratios (ORs), using numbers of events per number of treated and control patients. Fixed-effects and random-effects models were applied (17) . To evaluate heterogeneity, the Cochran test statistic Q was evaluated. As this test has low power at small sample sizes and excessive power when there are many studies, the quantity I 2 was also calculated (17) , which measures the percentage of total variation caused by heterogeneity rather than chance. Higgins et al (18) suggested values of 25%, 50%, and 75% for low, moderate, and high heterogeneity. Additionally, the τ 2 statistic is reported; this value was used to assign study weights under the random-effects model. To account for multiple comparisons, P values were adjusted by the global and sequential Bonferroni procedure and by false discovery rate (19, 20) .
RESULTS
A total of 451 abstracts were identified on preliminary search. Individual review of abstracts yielded nine RCTs that met inclusion criteria. Subsequent review of metaanalyses and references in included trials yielded two additional RCTs, bringing the total number of included studies to 11. A summary of trial characteristics is provided in Table 1 (4) (5) (6) (9) (10) (11) (12) (13) (20) (21) (22) (23) .
A summary of the risk of bias in each included study and overall is shown in Table 2 (4-6,9-13,20-23) and the Figure. Lack of blinding of patients and clinicians was present in all trials. Of the 11 total trials (4-6,9-13,21-24), seven were terminated early: one because of harm (23) , one because of futility (6, 22) , one because of prespecified criteria requiring a larger subsequent trial (21) , and four because of benefit (10-13).
Primary Meta-Analysis of All Included RCTs
Summary of key findings and GRADE recommendations for the primary analysis of all RCTs is shown in Table 3 . Despite inconsistent and/or absent imaging selection, varying IV TPA use in the endovascular arm, and inclusion of trials with a low rate of stent retriever use, functional independence was significantly improved in patients who underwent local endovascular therapy as opposed to standard care (OR, 1.779; 95% confidence interval [CI], 1.262-2.507; P o .001; Tables 3 and 4) (4-6,9-13,20-23). There was no significant difference between arms for the outcomes of mortality, hemicraniectomy, symptomatic or fatal intracranial hemorrhage, and symptomatic or fatal cerebral edema (Tables 3 and 4).
Subgroup Analysis 1: Only RCTs with Imaging Selection
A subgroup analysis limited to RCTs that used preprocedural imaging selection demonstrated a further increase in benefit for functional independence at 90 days (OR, 2.037; 95% CI, 1.527-2.718; P o .001), as well as a strengthening of the trend toward statistical benefit in 90-day mortality (OR, 0.771; 95% CI, 0.595-1.000; P = .05; Table 5 ) (5, 6, (9) (10) (11) (12) (13) 20, 22) . Similar to RCTs without preprocedural imaging selection, there were no significant differences (P 4 .05) noted between arms for the outcomes of mortality, hemicraniectomy, symptomatic or fatal intracranial hemorrhage, and symptomatic or fatal cerebral edema ( 
DISCUSSION
For patients with acute ischemic stroke, meta-analysis demonstrated a significant benefit of local endovascular therapy versus standard care in terms of functional independence. This benefit improved further on subgroup analyses that were limited to RCTs that had high stent-retriever use rates, used IV TPA in the endovascular arm if appropriate, and included careful preprocedural imaging selection to identify target occlusion in both treatment arms. Similar rates of mortality, hemicraniectomy, symptomatic or fatal intracranial hemorrhage, and symptomatic or fatal cerebral edema indicate that local endovascular therapy has a comparable safety profile to standard care.
Subgroup analysis of trials with isolated intraarterial TPA and/or mechanical thrombectomy without IV TPA in the endovascular arm did not demonstrate benefit in functional independence at 90 days. These results should be interpreted with caution, as the four RCTs included in this analysis had significant limitations aside from the lack of IV TPA in the endovascular arm. These limitations include predominantly small trial size, primary use of pharmacologic thrombectomy alone with inconsistent use of mechanical thrombectomy, longer times to ) demonstrated that, within the endovascular intervention arms, there was no significant difference in the degree of benefit between those who received endovascular therapy alone or in combination with IV TPA (25) . Several meta-analyses have been published that have assessed local endovascular therapy for acute ischemic stroke (26) (27) (28) (29) (30) (31) (32) (33) . Unlike prior meta-analyses, the present meta-analysis excludes RCTs with a control arm of sham/placebo to compare treatment versus the current standard of care, which consists of IV TPA if appropriate. Previous meta-analyses that included RCTs with a sham/placebo control arm may overestimate the relative benefit of local endovascular therapy compared with the previous standard of care (i.e., IV TPA). A secondary benefit of this approach is to reduce study heterogeneity. Moreover, subgroup analyses were performed to separate out trials that allowed for IV TPA use, if appropriate, in the endovascular arm and those that did not. Additional strengths of the present metaanalysis versus previous work are the updated literature search accounting for new trials, the rigorous application of the Cochrane risk of bias and GRADE qualityassessment tools, and the subgroup analysis of RCTs based on preprocedural imaging selection.
Many previous RCTs that did not demonstrate benefit of local endovascular therapy were marred by poor imaging selection (4, 22, 23) . They relied on cerebral angiography carried out after randomization and only in the endovascular arm. As a result, in these trials (7, 8) , the presence of vessel occlusion was unknown in the control arm and often not present on imaging in the endovascular arm. Other trials had inconsistent access to CT or MR angiography at the majority of study centers (6) . The present metaanalysis demonstrates the importance of patient selection with preprocedural imaging. Limiting local endovascular therapy treatment to patients with confirmed vessel occlusion on preprocedural imaging helps mitigate the risk of unwarranted intervention and can potentially identify those who have the most to gain by intervention if able to quantify salvageable brain tissue.
Older trials assessing endovascular therapy have been criticized for lack of or low rates of use of stent retrievers, which are thought to be technically superior in the performance of mechanical thrombectomy (9-13). The present meta-analysis lends support to these arguments by demonstrating a further strengthening of the statistical significance and degree of benefit within the subgroup of RCTs with majority stent-retriever use.
The present meta-analysis does have some limitations. First, most trials had some differences in inclusion criteria relating to time from onset of symptoms to intervention in the endovascular arm (2-6,9-13,21-23). Additionally, it was not possible to separate RCTs based on more complex imaging techniques and scoring systems, such as Alberta Stroke Program Early CT Score (10, 11) . It remains to be determined how these imaging protocols will best be incorporated in the patient-selection algorithm for local endovascular therapy. Moreover, the present analysis does not distinguish between endovascular pharmacologic and mechanical thrombectomy. It is important to note that, despite these differences, statistical measures of heterogeneity were low and nonsignificant for each outcome. It should be emphasized that the trials included in the present preprocedural imaging subgroup analysis tended to use mechanical thrombectomy more frequently than pharmacologic thrombectomy (5,9-13). Mechanical thrombectomy, particularly by stent retrievers, may be superior to pharmacologic thrombectomy, achieving faster and greater rates of technically successful recanalization (34) . As a result, this confounding factor may have biased our subgroup analysis results in favor of imaging selection. Further trials will be necessary to determine the optimal approach and timing for endovascular therapy and how to balance these approaches with IV thrombolysis.
Finally, after the positive results of MR CLEAN (9), a number of RCTs that were under way at the time of its publication (10-13) were terminated early as a result of the demonstrated efficacy in MR CLEAN (9) . In addition, all trials were unable to blind patients and physicians to treatment arm assignment (2) (3) (4) (5) (6) (9) (10) (11) (12) (13) (21) (22) (23) . This may lead to bias that can potentially overestimate benefit (15, 16, 35) . Consequentially, the confidence in each estimate was decreased by one point, as per GRADE criteria, to moderate (16) . Because of the early stoppage of all current RCTs in view of the benefit shown in MR CLEAN (9) and the inability to blind operating physicians and patients regarding choice of treatment, this will likely remain a permanent limitation in assessing quality of the current literature.
On a broader level, the results of the present analysis must be interpreted with caution, as all included studies were performed in academic centers with subspecialtytrained interventionalists and the capacity to perform procedures in rapid time-frame protocols (2-6,9-13,21-23). It remains to be determined if and how such complex care could be reproducibly implemented on a wide-scale basis, including in nonacademic centers. Cost-benefit analyses must be carried out to assess the best means to implement such therapies, such that the necessary resources are available.
CONCLUSIONS
The present meta-analysis provides moderate-quality evidence for the benefit of local endovascular therapy for acute ischemic stroke in achieving functional independence. There were no significant differences between local endovascular therapy and standard care for the outcomes of mortality, hemicraniectomy, symptomatic or fatal intracranial hemorrhage, and symptomatic or fatal cerebral edema. Subgroup analyses suggest that appropriate imaging selection to identify target occlusions, stent-retriever use, and concurrent use of IV TPA, if appropriate, strengthen the benefit of endovascular therapy. Further cost-benefit analyses are necessary to determine the feasibility of implementing endovascular stroke therapy on a wider scale.
